We advised Precigen on the SEC-registered offering

Davis Polk advised Precigen, Inc., as issuer, in connection with the SEC-registered offering of an aggregate of 42,857,143 shares of its common stock, no par value per share, having an aggregate offering price of approximately $75 million before underwriting discounts and estimated expenses of the offering. The common stock of Precigen, Inc. is listed on the Nasdaq Global Select Market under the symbol “PGEN.”

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. The company’s technologies enable it to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Arisa Akashi Sin and Helen H. Ferrall. Partner David R. Bauer and associates Brette L. Trost and Adrian Rabin provided intellectual property advice. Partner Michael Farber and associate Michael Mirabella provided tax advice. Counsel Sarah E. Kim provided 1940 Act advice. All members of the Davis Polk team are based in the New York office.